• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
【24h】

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.

机译：抗精神病药治疗精神分裂症的有效性：前瞻性观察研究（IC-SOHO）对奥氮平，喹硫平，利培酮和氟哌啶醇进行的6个月中期分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study was designed to provide information regarding use and outcome of antipsychotic treatments in a large, diverse population in real practice settings. METHOD: Outpatients with schizophrenia (ICD-10 or DSM-IV) who initiated or changed to a new antipsychotic entered this 3-year, naturalistic, prospective observational study. Four monotherapy treatment groups were defined according to the antipsychotic prescribed at baseline, namely olanzapine, risperidone, quetiapine, and haloperidol. Efficacy was assessed using the Clinical Global Impressions-Severity of Illness rating scale (CGI-S), inclusive of subscales for positive, negative, depressive, and cognitive symptoms. Tolerability was assessed by adverse event questionnaires and weight measurements. Six-month findings are described. RESULTS: At baseline, 5833 participants were prescribed monotherapy and the mean severity of illness was moderate to marked (CGI-S). At 6 months, olanzapine resulted in significantly greater improvements in overall, positive, negative, depressive, and cognitive symptoms compared with quetiapine, risperidone or haloperidol (p <.001). Improvements in overall, negative, and cognitive symptoms were significantly higher for risperidone compared with haloperidol (p <.001), whereas improvements across all symptoms were comparable for quetiapine and haloperidol. Extra-pyramidal symptoms and tardive dyskinesia decreased compared with baseline in the olanzapine, quetiapine, and risperidone groups but increased in the haloperidol group (p <.001, likelihood of extrapyramidal symptoms with haloperidol compared with olanzapine, quetiapine, or risperidone). Sexual function adverse events were most prominent in the haloperidol and risperidone treatment groups. Weight change was significantly greater for olanzapine compared with the other antipsychotics (p <.001). CONCLUSION: Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia.
机译：背景：洲际精神分裂症门诊健康结果（IC-SOHO）研究旨在提供有关在实际实践中在大量不同人群中使用抗精神病药物和治疗效果的信息。方法：开始或改变为新的抗精神病药的精神分裂症门诊患者（ICD-10或DSM-IV）参加了这项为期3年的，自然主义的，前瞻性的观察性研究。根据基线时指定的抗精神病药定义了四个单药治疗组，即奥氮平，利培酮，喹硫平和氟哌啶醇。使用临床总体印象-疾病严重性等级量表（CGI-S）评估疗效，包括阳性，阴性，抑郁和认知症状的分量表。通过不良事件问卷和体重测量评估耐受性。描述了六个月的发现。结果：在基线时，有5833名参与者被处方采用单一疗法，平均疾病严重程度为中度至明显（CGI-S）。与喹硫平，利培酮或氟哌啶醇相比，奥氮平在6个月时总体，阳性，阴性，抑郁和认知症状的改善明显更大（p <.001）。与氟哌啶醇相比，利培酮的总体，阴性和认知症状的改善显着更高（p <.001），而喹硫平和氟哌啶醇在所有症状上的改善均相当。与基线相比，奥氮平，喹硫平和利培酮组的锥体外系症状和迟发性运动障碍减少，而氟哌啶醇组则增加（p <.001，与奥氮平，喹硫平或利培酮相比，氟哌啶醇的锥体外系症状的可能性）。在氟哌啶醇和利培酮治疗组中，性功能不良事件最为明显。与其他抗精神病药相比，奥氮平的体重变化明显更大（p <.001）。结论：我们的结果支持先前报道的非典型抗精神病药，特别是奥氮平对精神分裂症患者的积极影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号